CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

COVID-19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug562 COVID-19 infection Wiki 0.71
drug2311 Questionnaire Wiki 0.14

Correlated MeSH Terms (10)

Name (Synonyms) Correlation
D001167 Arteritis NIH 0.50
D011111 Polymyalgia Rheumatica NIH 0.41
D013700 Giant Cell Arteritis NIH 0.41
D003095 Collagen Diseases NIH 0.35
D015535 Arthritis, Psoriatic NIH 0.35
D012216 Rheumatic Diseases NIH 0.29
D008180 Lupus Erythematosus, Systemic NIH 0.29
D001168 Arthritis NIH 0.20
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (3)

Name (Synonyms) Correlation
HP:0012089 Arteritis HPO 0.50
HP:0002725 Systemic lupus erythematosus HPO 0.29
HP:0001369 Arthritis HPO 0.20

There are 2 clinical trials

Clinical Trials

1 Assessment of Health-related Quality of Life and Patient-centered Outcomes After Hospitalization for COVID-19: A Multicenter Prospective Cohort Study

The present study aims to assess the determinants of health-related quality of life and patient-centered long-term outcomes among survivors of hospitalization for Covid-19 in Brazil. The investigators will conduct a multicenter prospective cohort study nested in randomized clinical trials (coalition Covid-19 Brazil initiative) originally designed to assess the effects of specific Covid-19 treatments. Adult survivors of hospitalization due to proven or suspected SARS-CoV-2 infection will be followed up for a period of one year by means of structured telephone interviews. The primary outcome is one-year health-related quality of life assessed by the EQ-5D-3L. Secondary outcomes include all-cause mortality, rehospitalizations, return to work or study, physical functional status assessed by the Lawton & Brody Instrumental Activities of Daily Living Scale, dyspnea assessed by the modified medical research council dyspnea scale, need of long-term ventilatory support, symptoms of anxiety and depression assessed by the Hospital Anxiety and Depression Scale, and symptoms of posttraumatic stress disorder assessed by the Impact of Event Scale-revised. Four sets of variables (1-demographic characteristics, 2-pre-morbid state of health, 3-characteristics of acute illness, and 4- specific Covid-19 treatments received) will be assessed as potential risk factors for health-related quality of life and secondary outcomes.

NCT04376658 Quality of Life Long-term Outcomes Coronavirus Infection Other: COVID-19
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).

Measure: One-year utility score of health-related quality of life

Time: The outcome will be assessed 12 months after enrollment.

Secondary Outcomes

Description: Incidence of all-cause mortality.

Measure: Incidence of all-cause mortality

Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.

Description: Incidence of all-cause rehospitalizations.

Measure: Incidence of rehospitalizations

Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.

Description: Percentage of return to work or study among patients that were working or studying at the moment of hospitalization.

Measure: Percentage of return to work or study

Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.

Description: The outcome will be assessed using the Lawton & Brody Instrumental Activities of Daily Living Scale (the score ranges from 0 to 8, with higher scores indicating less dependence).

Measure: Score of Instrumental Activities of Daily Living

Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.

Description: The outcome will be assessed using the modified medical research council dyspnea scale. Scores ranges from 0 to 4, with higher scores indicating worse symptoms.

Measure: Score of dyspnea

Time: The outcome will be assessed 3, 6, 9, and 12 months after enrollment.

Description: Percentage of patients requiring oxygen therapy, non-invasive ventilation, or mechanical ventilation.

Measure: Percentage of long-term ventilatory support need

Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.

Description: The outcome will be assessed using the Hospital Anxiety and Depression Scale (anxiety and depression scores range from 0 to 21, with higher scores indicating worse symptoms).

Measure: Symptoms of anxiety and depression

Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.

Description: The outcome will be assessed using the Impact Event Scale-Revised (the score ranges from 0 to 88, with higher scores indicating worse symptoms).

Measure: Symptoms of posttraumatic stress disorder

Time: The outcome will be assessed 3, 6, 9 and 12 months after enrollment.

Description: The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).

Measure: Utility score of health-related quality of life at 3, 6, and 9 months

Time: The outcome will be assessed 3, 6, and 9 months after enrollment.

Description: The outcome will be assessed using the visual analogue scale of the Brazilian version of the Euroqol-5D-3L questionnaire (EQ-VAS; score range from o to 100, with higher scores indicating better self-rated health).

Measure: Score of self-rated health

Time: The outcome will be assessed 3, 6, 9, and 12 months after enrollment.

2 Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a

The Canadian Paediatric Society recommends breastfeeding during COVID-19 infection. Human milk is the best form of infant nutrition providing significant protection against many illnesses for term and preterm infants. The impact of a pandemic on breastfeeding is unknown. This study seeks to address this public health issue. Breastmilk will be collected from mothers positive for COVID-19. Samples will be analyzed for the COVID-19 virus specific nucleic acid and antibody in real-time and results will be immediately disseminated to relevant organizations to inform local, national and international guidelines surrounding breastfeeding to protect the health of infants.

NCT04453969 SARS-CoV2 Breastmilk Other: COVID-19

Primary Outcomes

Measure: SARS-CoV-2 in breastmilk

Time: 2-6 months

Measure: SARS-CoV-2 antibody in breastmilk

Time: 2-6 months

No related HPO nodes (Using clinical trials)